[go: up one dir, main page]

AR086259A1 - Procesos para la preparacion de inhibidores del virus de la hepatitis c - Google Patents

Procesos para la preparacion de inhibidores del virus de la hepatitis c

Info

Publication number
AR086259A1
AR086259A1 ARP120101561A ARP120101561A AR086259A1 AR 086259 A1 AR086259 A1 AR 086259A1 AR P120101561 A ARP120101561 A AR P120101561A AR P120101561 A ARP120101561 A AR P120101561A AR 086259 A1 AR086259 A1 AR 086259A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
formula
compound
hepatitis
Prior art date
Application number
ARP120101561A
Other languages
English (en)
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of AR086259A1 publication Critical patent/AR086259A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/005Enzyme inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/36Extraction; Separation; Purification by a combination of two or more processes of different types

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Procesos sintéticos útiles en la preparación de compuestos de fórmula (1) que son útiles como inhibidores de la proteasa NS3 del virus de la hepatitis C (VHC) y tienen aplicación en el tratamiento de afecciones causadas por el VHC.Reivindicación 1: Un proceso para preparar un compuesto de fórmula (1), en la que: A y E son independientemente un enlace directo; R1 es -NH(alquilo C1-8); R2 es alquilo C1-8; R3 se selecciona independientemente entre el grupo que consiste en alquilo C1-8, alquil C1-8(cicloalquilo C3-8) y alquil C1-8(cicloalquilo C3-8) sustituido; o cada uno de R4 y R5 se selecciona independientemente entre el grupo que consiste en H, alquilo C1-8, cicloalquilo C3-8, alquil C1-8(cicloalquilo C3-8) y alquil C1-8(cicloalquilo C3-8) sustituido, o R4 y R5 pueden tomarse juntos para formar un cicloalquilo C3-8; R6 y R7 son independientemente metilo; comprendiendo el proceso: hacer reaccionar un compuesto de fórmula (2), en la que A, E, R1, R2, R3, R4, R5, R6 y R7 son como se han definido anteriormente, con un agente de oxidación seleccionado entre el grupo que consiste en KMnO4, NaMnO4, K2FeO4, V2O5, RuO2, NaNO2, CrO3, K2CrO4, K2Cr2O7, H5PV2Mo10O4, peróxidos y PhI(OAc)2, en presencia de al menos un catalizador para producir un compuesto de fórmula (1).
ARP120101561A 2011-05-04 2012-05-03 Procesos para la preparacion de inhibidores del virus de la hepatitis c AR086259A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161482592P 2011-05-04 2011-05-04

Publications (1)

Publication Number Publication Date
AR086259A1 true AR086259A1 (es) 2013-12-04

Family

ID=47108028

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120101561A AR086259A1 (es) 2011-05-04 2012-05-03 Procesos para la preparacion de inhibidores del virus de la hepatitis c

Country Status (17)

Country Link
US (2) US20140044759A1 (es)
EP (2) EP2704576A4 (es)
JP (2) JP2014513127A (es)
KR (2) KR20140030169A (es)
CN (2) CN103501608A (es)
AR (1) AR086259A1 (es)
AU (2) AU2012250799A1 (es)
BR (2) BR112013027652A2 (es)
CA (2) CA2833887A1 (es)
CO (1) CO6801768A2 (es)
IL (1) IL228601A0 (es)
MX (2) MX2013012771A (es)
RU (2) RU2013153533A (es)
SG (1) SG194711A1 (es)
TW (1) TW201247668A (es)
WO (2) WO2012151271A1 (es)
ZA (1) ZA201308011B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011014487A1 (en) 2009-07-30 2011-02-03 Merck Sharp & Dohme Corp. Hepatitis c virus ns3 protease inhibitors
BR112015031979B1 (pt) * 2013-06-19 2022-05-24 Aicuris Anti-Infective Cures Gmbh Letermovir, formulação farmacêutica oral sólida, uso de uma formulação farmacêutica oral sólida, e processo para preparar letermovir
EP3592732B1 (en) * 2017-03-07 2025-04-09 Orion Corporation Manufacture of a crystalline pharmaceutical product
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR044694A1 (es) * 2003-06-17 2005-09-21 Schering Corp Proceso y compuestos intermedios para la preparacion de (1r, 2s,5s) - 3 azabiciclo [3,1,0] hexano-2- carboxamida, n- [3- amino-1- (ciclobutilmetil) - 2, 3 - dioxopropil] -3- [ (2s) - 2 - [[ [ 1,1- dimetiletil] amino] carbonilamino] -3,3-dimetil -1- oxobutil]-6,6 dimetilo
AR056805A1 (es) * 2005-11-14 2007-10-24 Schering Corp Un proceso para oxidacion para la preparcion de n- (3- amino-1- ( ciclobutilmetil) -2,3- dioxopropil ) -3-(n-(( ter-butilamino) carbonil )-3- metil- l- valil) -6,6- dimetil-3- azabiciclo (3.1.0) hexano -2- carboxamida y compuestos ralacionados
CN101495095B (zh) * 2006-04-28 2013-05-29 默沙东公司 通过受控的沉淀来沉淀和分离6,6-二甲基-3-氮杂-双环[3.1.0]己烷-酰胺化合物的方法和含有其的药学制剂
US8420122B2 (en) * 2006-04-28 2013-04-16 Merck Sharp & Dohme Corp. Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
ES2439246T3 (es) * 2006-12-20 2014-01-22 Merck Sharp & Dohme Corp. Procedimiento de preparación de (1R,2S,5S)-N-[(1S)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil]-3-[(2S)-2-[[[(1,1-dimetiletil)amino]carbonil]amino]-3,3-dimetil-1-oxobutil]-6,6-dimetil-3-azabiciclo[3.1.0]hexan-2-carboxamida
SI2118098T1 (sl) * 2007-02-01 2015-01-30 Janssen R&D Ireland Polimorfne oblike makrocikličnega inhibitorja HCV
JP4803074B2 (ja) * 2007-03-06 2011-10-26 日産化学工業株式会社 アルコール酸化触媒およびその合成方法
ATE519503T1 (de) * 2007-09-14 2011-08-15 Schering Corp Verfahren zur behandlung von patienten mit hepatitis c
DE102009000662A1 (de) * 2009-02-06 2010-08-12 Evonik Degussa Gmbh Verfahren zur Herstellung von Aldehyden und Ketonen aus primären und sekundären Alkoholen

Also Published As

Publication number Publication date
CA2832869A1 (en) 2012-11-08
BR112013027652A2 (pt) 2016-07-26
MX2013012773A (es) 2013-11-21
SG194711A1 (en) 2013-12-30
WO2012151271A1 (en) 2012-11-08
MX2013012771A (es) 2013-11-21
KR20140022855A (ko) 2014-02-25
EP2704576A4 (en) 2014-12-10
JP2014515764A (ja) 2014-07-03
CO6801768A2 (es) 2013-11-29
AU2012250811A1 (en) 2013-12-19
US20140044759A1 (en) 2014-02-13
KR20140030169A (ko) 2014-03-11
CN103476260A (zh) 2013-12-25
IL228601A0 (en) 2013-12-31
RU2013153588A (ru) 2015-06-10
EP2704570A4 (en) 2015-02-18
JP2014513127A (ja) 2014-05-29
WO2012151283A1 (en) 2012-11-08
EP2704570A1 (en) 2014-03-12
BR112013027642A2 (pt) 2016-07-26
CA2833887A1 (en) 2012-11-08
EP2704576A1 (en) 2014-03-12
TW201247668A (en) 2012-12-01
US20140058116A1 (en) 2014-02-27
ZA201308011B (en) 2015-05-27
CN103501608A (zh) 2014-01-08
AU2012250799A1 (en) 2013-10-10
RU2013153533A (ru) 2015-06-10
NZ617300A (en) 2015-06-26

Similar Documents

Publication Publication Date Title
PE20121118A1 (es) Compuestos de haloalquil heteroaril benzamida
CO6361922A2 (es) Inhibidores del virus de la hepatitis c
AR075332A1 (es) Dionas ciclicas como herbicidas
AR086019A1 (es) COMPUESTOS DE PIRROLO SULFONAMIDA PARA MODULACION DE LA ACTIVIDAD DEL RECEPTOR HUERFANO g RELACIONADO AL RECEPTOR NUCLEAR HUERFANO RAR (RORg, NR1F3) Y PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS Y AUTOINMUNES CRONICAS
PE20120995A1 (es) Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral
PE20091103A1 (es) Inhibidores de la polimerasa virica
UY35641A (es) PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO)
AR079226A1 (es) Espiroindolinona- pirrolidinas, procesos de preparacion y uso de los mismos para el tratamiento y profilaxis del cancer
PE20130010A1 (es) Derivado de 1,3,4,8-tetrahidro-2h-pirido[1,2-a]pirazina como inhibidor de la integrasa del vih
PE20160200A1 (es) Inhibidores de bromodominios
PE20171341A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas
CO6561783A2 (es) Inhibidores del virus flaviviridae
UA116087C2 (uk) Композиція для лікування вірусу гепатиту c
UY29704A1 (es) Inhibidores macrociclicos del virus de la hepatitis c
CO6420390A2 (es) Inhibidores de la replicación del virus de la hepatitis c.
UY35155A (es) Derivados cíclicos de nucleósidos y usos de los mismos
UY32325A (es) Inhibidores de ns3 proteasa del vhc
CO6541557A2 (es) Inhibidores del virus de hepatitis c
CO2017001178A2 (es) Derivado de piridona que tiene un grupo tetrahidropiranil metilo
PE20141041A1 (es) Compuestos, metodos y formulaciones parasiticidas
WO2013074386A3 (en) Hcv ns3 protease inhibitors
MX362060B (es) Compuestos antivirales inhibidores del virus de hepatitis c (vhc) ns5b.
PE20120937A1 (es) Compuestos derivados de quinolina y quinoxalina como agentes antivirales
PE20142452A1 (es) AMIDAS CICLICAS COMO INHIBIDORES DE MetAP-2
PE20151718A1 (es) Compuestos piridinilpirazoloquinolina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal